

Granules India

BSE SENSEX
30,465

S&P CNX
9,429

CMP: INR149 TP: INR200 (+34%)

Buy



Stock Info

Bloomberg	GRAN IN
Equity Shares (m)	229
52-Week Range (INR)	157/91
1, 6, 12 Rel. Per (%)	4/28/-6
M.Cap. (INR b)	33.8
M.Cap. (USD b)	0.5
Avg Val, INRm	197.0
Free float (%)	46.5

Financials Snapshot (INR b)


Y/E Mar	2017	2018E	2019E
Net Sales	14.4	17.4	23.9
EBITDA	3.0	3.7	5.2
PAT	1.7	2.1	2.9
EPS (INR)	7.3	8.1	11.4
Gr. (%)	32.7	12.3	39.9
BV/Sh (INR)	43.5	60.4	69.1
RoE (%)	20.0	16.4	17.6
RoCE (%)	17.0	14.7	16.8
P/E (x)	20.5	18.3	13.1
P/BV (x)	3.4	2.5	2.2

Shareholding pattern (%)

As On	Mar-17	Dec-17	Mar-16
Promoter	53.5	51.9	51.1
DII	1.6	1.2	1.2
FII	10	6	6.4
Others	35	40.9	41.3

FII Includes depository receipts

Stock Performance (1-year)



Combination of strong growth and multiple re-rating

From being one of the largest Paracetamol API manufacturers for regulated markets, Granules India (GRAN) has now ventured into CRAMS and US Rx business, where it can leverage its competitive advantage of being a high-quality, low-cost producer. Despite delivering ~40% PAT CAGR over last five years, we expect GRAN to deliver ~35% PAT CAGR till FY20E. This will be led by (1) capacity expansion in the base business, 2) doubling of revenues (INR2.3b in FY20E from INR1.0b in FY17) and expansion in EBITDA margin (>30% in FY20E from ~21% in FY17) in Omnichem CRAMS JV, and 3) new US generic business sales of ~USD85m in FY20 v/s nil currently.

Base business – augmented capacity to fuel growth; focus on formulations to boost margins

- GRAN is among the largest manufacturers of Paracetamol and Ibuprofen APIs for the regulated markets. Along with this, it has been supplying Metformin, Guaifenesin and Methacarbamol API/PFI/formulations. Until FY17, ~85% of its business has come from these five base molecules. A higher focus on formulations over past 4-5 years (revenue contribution up >10%) has helped GRAN expand its EBITDA margin from 11% in FY13 to ~21% in FY17.
- Currently, API is running at 100% capacity and PFI at 73% utilization. The company had planned to increase its API capacity by ~40% and PFI capacity by >20% by March 2017, which will also help fuel growth in formulations (as the company is dependent on backward integration). This will help grow the base business at mid-to-high teens till at least FY20 (~16% CAGR over FY17-20E v/s ~7% in FY17).

US business – plans niche foray into Rx business

- GRAN is planning to file ~25-30 ANDAs in the US till FY19E. Of these, ~10 complex ANDAs will be filed from its US-based Virginia facility and the rest from its India-based facility in Gagilapur. The company has already filed two complex generic ANDAs from its Virginia facility in March/April-17 (market size of USD660m), where it expects to be 3rd/4th player at the time of launch (2HFY19). We expect own new filings for GRAN to contribute USD50-60m in FY20E.
- The company has also acquired the marketing rights from US Pharma for its four ANDAs (scheduled to be launched from late FY18E to FY19E). The market size for these products is >USD4b, and revenue potential could be USD30-35m in FY19E.
- Although we are already building in R&D spend of ~USD12m for FY19E, full-year revenue from own filings will start only FY20 onward. Despite this, we estimate an improvement in the consolidated EBITDA margin by 100bp due to traction in the base business and a shift in product mix toward formulations.

Kumar Saurabh (Kumar.Saurabh@MotilalOswal.com); +91 22 6129 1519

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

Our Initiating coverage report on Granules India



Omnichem CRAMs JV: FDA approval expected in FY18; margins to reach >30% in FY19E

- Granules-Omnichem is a 50:50 JV between GRAN and Ajinomoto-Omnichem, Belgium. Omnichem would be transferring large-scale production of intermediates and APIs to Granules-Omnichem JV. It will also provide full support for quality, engineering, tech transfer, procurement, sales and management-related matters.
- Revenue is likely to grow rapidly beyond FY18 post site approvals for customers (US FDA inspection complete). We expect the EBITDA margin to reach >30% from ~21% currently, as API supply to innovators will start FY19E onward. Besides de-risking, it will provide a steady revenue stream with healthy margins. We see revenue potential of INR450m by FY20E.

Return from investments visible; adding legs to growth

- GRAN plans to invest INR10.5b over three years starting FY16. Over FY16 and FY17, it incurred capex of ~INR1.3b and INR3.4b, respectively. Although full-scale benefit of these investments will be visible from FY19/20E, FY18E will be a critical year as 1) revenue contribution from capacity expansion in traditional business will kick in, 2) filings from the US (already done 2 and ~8 by FY18-end) will provide visibility on areas of investment in the US, 3) FDA approval for the Omnichem JV plant will provide visibility on API sales (and in turn lead to margin improvement to >30% from ~21% currently) and 4) oncology plant should be ready.
- The company plans to incur capex of INR5.5-6.0b in FY18. It intends to invest ~INR4.5b in the US (USD10m in FY16, USD18m in FY17 and ~USD40m in FY18), mainly toward R&D (~60-65% of total) and the rest toward expanding capacity/buying equipment. Capex of INR2.1b has been incurred on traditional business capacity expansion (revenue to start 2QFY18 onward), while INR2.6b will be spent on developing oncology API/formulations plant (to get commissioned by FY19 beginning).

PAT CAGR of ~35% till FY20, despite full R&D expensing

- We expect PAT CAGR of ~35% over FY17-20E. This is after assuming R&D expense of USD12m (5.5% of FY17E sales). This strong growth will be driven primarily by ramp-up of the base business (led by capacity expansion), a shift in product mix, and Omnichem JV and OTC business expansion. Although FY19 will be the first year of US business sales, the full impact of investments in that country will be visible from FY20.

Trades at ~13x FY19E PER; US business ramp-up an option value

- GRAN trades at ~13x FY19E EPS (despite assuming >10% equity dilution). We believe the stock has the potential to deliver >50% return over next 12-18 months, led by multiple re-rating (to >18x forward earnings) and a strong EPS CAGR of ~35% till FY20. At 18x FY19E PER, fair value of the stock is INR200.
- **Key risks to our estimates:** (1) Higher competition in products like Metformin and Paracetamol. (2) Delay in ramp-up of the US business. (3) Regulatory risk for its manufacturing facility.

Legacy business: Capacity expansion to fuel growth

- GRAN plans to expand its API capacity by ~40% and PFI capacity by >20% by mid-FY18.
- This will help it meet growing demand for Paracetamol/Metformin/Guaifenesin molecules across the globe. At present, the top five molecules contribute 85% of its total sales.

Strong base business; augmented capacity to fuel growth

- GRAN is among the largest manufacturers of Paracetamol and Ibuprofen APIs for the regulated markets. Along with this, it has been supplying Metformin, Guaifensin and Methacarbamol APIs. Until FY17, ~85% of its business has come from these five base molecules. Currently, API is running at 100% capacity and PFI at 73% utilization.
- The company is increasing its API capacity for Metformin, Paracetamol and Guaifensin by 15,000 TPA, and PFI capacity by >20%. Paracetamol supply will commence from 2QFY18, while Metformin supply to developed markets will start from FY19 (as clinical trial will be required). This capacity expansion in PFI/API will also help fuel growth in formulations (as the company is dependent on backward integration). This will help grow the base business at high-teens till at least FY20.
- GRAN’s base business covers 75% of the analgesics market (Paracetamol, Ibuprofen) and ~50% of the diabetes market (Metformin). Paracetamol, Ibuprofen and Metformin have maintained their status as the first line of defense in their respective segments, and have no direct replacements in the pipeline.

Exhibit 1: Molecule-wise share (%)




Exhibit 2: Geography-wise share (%)





Exhibit 3: Product mix changing (%)



Source: Company, MOSL

API capacities: GRAN's existing API business is primarily driven by higher capacities, which augment production yield for the five APIs and improve profitability.

Over the years, GRAN has increased Paracetamol capacity from 8,000MTPA to 18,000MTPA, becoming the second largest Paracetamol producer in the world for the regulated markets (behind Mallinckrodt). Due to growing demand for internal and external consumption of Paracetamol in the regulated markets, GRAN has expanded its API capacities via de-bottlenecking.

Similarly, it intends to expand Metformin capacities in two phases (from 2,000MTPA to 9,000MTPA) by FY19E. Post expansion, GRAN would become one of the top three Metformin API producers in the world. The Metformin API market is growing at 8-10%/year, reflecting healthy demand for Metformin molecules due to combination products.


Exhibit 4: Growing API capacities

	FY08	FY12	FY15	FY16	FY18E
Paracetamol	8,000	10,000	14,400	18,000	24,000
Metformin	960	2,000	2,000	2,000	9,000
Ibuprofen	3,600	4,800	4,800	4,800	4,800
Guanfenesin	640	1,200	1,200	1,200	3,200
Methocarbamol	96	180	360	360	360

Source: Company, MOSL


PFI capacities: GRAN has one of the largest PFI capacities globally at Gagilarpur in Andhra Pradesh, India. It is the only company in the world with capacity to handle 6MT PFI batch size. This gives GRAN a significant edge over competitors in terms of scale and profitability. GRAN already expanded its PFI capacity to 18,400MTPA in FY16 from 13,200MTPA in FY15. These PFI capacities are operating at 70-75% utilization, which is enough to support 17-18% growth in the existing PFI business over next two years.

Exhibit 5: PFI capacities at 18,400MTPA




Source: Company, MOSL

Finished dosages capacity: GRAN had set up its first formulations facility in FY08, with annual capacity of 6b tablets. In FY12, it tripled this capacity to 18b tablets. It is still operating at 50-55% utilization and can comfortably support 26-30% revenue CAGR in the existing formulations business over next two years.

Exhibit 6: Finished dosage capacity at 18b tablets

Source: Company, MOSL

Exhibit 7: Utilization levels of the base business (%)

Source: Company, MOSL

Exhibit 8: API capacities of top five molecules

Paracetamol Regulated Market Suppliers (MTPA)	
Mallinckrodt	25,000
Granules	18,000
Novocel	6,000
Ibuprofen Suppliers (MTPA)	
Shasun	6,000
IOL Chemicals	6,000
Albemarle	5,200
BASF	5,000
Granules Biocause	4,800
Metformin Suppliers (MTPA)	
Granules	2,000
USV Ltd	10,100
Wanbury	9,000
Harman	6,000
Methocarbamol Suppliers (MTPA)	
Granules	360
Synthochem	250
Guaifenesin Suppliers (MTPA)	
Granules	1,200
Synthochem	800


Source: Company, MOSL

US business: Plans niche foray into Rx business

Full potential will be visible in FY20

- GRAN is planning to file ~25-30 ANDAs in the US till FY19. Of these, ~10 complex ANDAs will be filed from its US-based Virginia facility and the rest of them from the India-based facility in Gagilapur. In FY18, GRAN plans to file 10-12 ANDAs, of which six will be filed from Gagilapur and the rest from Virginia.
- **Virginia facility – focus on complex filings:** GRAN acquired the Virginia-based facility for a consideration of USD1.5m. Through this plant, GRAN can focus on products with specific release properties, ODTs and DEA-controlled substances. The company plans to invest ~USD70m in this facility toward capacity expansion (currently capacity of 0.5b tablets), R&D and employee addition.
- The company has already filed two complex generic ANDAs from its Virginia facility in March/April-17 (market size of USD660m), where it expects to be 3rd/4th player at the time of launch (2HFY19). We expect own new filings for GRAN to contribute USD50-60m in FY20E.
- **US Pharma product acquisition to drive growth from FY19:** GRAN has also acquired marketing rights from US Pharma for four ANDAs (scheduled to be launched from late-FY18 to FY19). The market size of these products is >USD5b, with revenue potential of USD30-35m in FY19E.
- **Costs to be built in P&L from FY19E, but revenue potential to be visible from FY20:** Although we are already building in R&D spend of ~USD12m for FY19E, full-year revenue from own filings will start only FY20 onward. Despite this, we estimate an improvement in the consolidated EBITDA margins of 100bp due to traction in the base business and a shift in the product mix toward formulations.

Revenues from US formulation business will start contributing from FY19 (~20% of sales)



Source: Company, MOSL

Omnichem CRAMs JV – entry into high-value APIs

Partner profile: Hubei Biocause is a public listed company involved in the pharmaceuticals, chemicals and new energy fuel businesses. Biocause's pharmaceuticals business involves contract research, contract manufacturing and production of APIs, intermediates and formulations, including tablets, granules and capsules. Biocause is one of the leading pharmaceutical product producers and exporters to China, with a strong production, R&D and quality system. The company has eight APIs registered with the FDA and four APIs with CEP.

Joint venture details: The JV between Biocause and GRAN had set up a facility in Wuhan, China to manufacture Ibuprofen for the regulated markets. Currently, it is operating at 4,800MTPA capacity, making it among the five largest Ibuprofen suppliers in the world.

Granules-Omnichem JV: Established in FY15


Partner profile: Ajinomoto-Omnichem is a Belgium-based company specializing in the manufacture of pharmaceutical products and fine chemicals. It is a wholly owned subsidiary of Japan-based Ajinomoto Co Inc (known for amino acids and food products). Omnichem, a division of Ajinomoto-Omnichem, focuses on development and manufacture of intermediates and active ingredients for the pharmaceutical industry (CRAMs). Each project is supported by an R&D team of ~80 people, who work on integrating the first lab experiments and pilot trials to full industrial production while maintaining confidentiality.

Omnichem JV sales expected to reach INR4.5b by FY20

Granules-Omnichem is a 50:50 JV between GRAN and Ajinomoto-Omnichem, Belgium. Omnichem would be transferring large-scale production of intermediates and APIs to Granules-Omnichem JV. It will also provide full support for quality, engineering, tech transfer, procurement, sales and management-related matters. Inspection at this facility is already completed in 3QFY17, and we expect EIR to come in 1HFY18. API supply to developed markets will start from FY19. Till the time FDA approval is not granted, the JV will continue to manufacture various intermediates for Omnichem. Once approvals are in place, the JV would start manufacturing high-value APIs for Omnichem's CRAMs customers. These APIs are likely to be sold to innovators and MNCs, helping them compete with generic players.

In FY17, this business generated revenue of ~INR2b. However, upon required regulatory approvals for products, Omnichem JV sales are expected to reach a peak of INR4.5b by FY20. These product approvals should kick in from FY18. Until then, the JV would continue supplying intermediates to Omnichem from this facility, which reported sales of INR1,000m in FY17. It is likely to achieve >30% EBITDA margin by selling high-value APIs (Oncology, CVS, etc.) to innovators.

Exhibit 9: Expect significant ramp-up in FY19




Source: Company, MOSL

Return from investments visible; adding legs to growth

- GRAN plans to invest INR10.5b over three years starting FY16. In FY16 and FY17, it incurred capex of ~INR1.3b and INR3.4b, respectively. Although full-scale benefits of these investments will be visible from FY19/20E, FY18E will be a critical year as: 1) revenue contribution from capacity expansion in traditional business will kick in, 2) filings from the US (already done 2, and ~8 by FY18E-end) will provide visibility on areas of investment in that country, 3) FDA approval to Omnicem JV plant will provide visibility on API sales from this plant (and, in turn, lead to margin improvement to >30% from ~21% currently) and 4) oncology plant should be ready.
- The company plans to incur capex of INR5.5-6.0b in FY18. It plans to invest ~INR4.5b in the US (USD10m in FY16, USD18m in FY17 and ~USD40m in FY18), mainly on R&D (~60-65% of total) and the rest on expanding capacity and buying equipment. Capex of INR2.1b has been incurred on traditional business capacity expansion (revenue contribution to start from 2QFY18), while INR2.6b will be spent on developing the oncology API/formulations plant (to get commissioned by FY19 beginning).

Exhibit 10: Total planned capex of ~INR10.5b over FY16-19E (INR m)



Source: Company, MOSL

Already secured line of credit to fund investments; equity raising is another

option: GRAN plans to invest ~INR5.5-6.0b in FY18E and ~INR2.5b in FY19E. It will generate ~INR3.5b through internal accruals, while the rest can be funded via debt/equity. The company has already has a line of credit of ~USD60m at an attractive rate of EURIBOR+2%.

Strong regulatory history

- At present, the company conducts business via six API/intermediate facilities, two PFI facilities and two formulation facilities. There is also one API facility under construction for multi-product APIs in Vizag.
- Historically, GRAN has demonstrated a strong regulatory record, with no warning letter or import alert for any facility in last eight FDA inspections.

Exhibit 11: List of plants and recent inspections outcome

Locations	Products	Approvals
API facilities		
Jeedimetla	Metformin,	USFDA, KFDA, TGA, EDQM
Bothapally 1	Paracetamol	USFDA, WHO, GMP, EDQM, Infarmed (EU) approved
Bothapally 2	Intermediate (Auctus)	
Wuhan	Ibuprofen	USFDA, EDQM, TPD – Canada, MCC approved
Vizag 1	Multiproduct (Auctus)	US FDA approved
Vizag 2	Oncology (Omnichem JV)	Yet to approve
Vizag 3	Multiproduct (Granules)	Under Development
PFI facilities		
Jeedimetla	Multiproduct small scale	USFDA, Australian TGA, German HA approved
Gagilapur	Multiproduct large scale	USFDA, German HA, Australian TGA approved
FD facilities		
Gagilapur	Tablets	Infarmed (EU), USFDA
US	Complex product filings	

Source: Company, MOSL

Building a strong management team

Granule is building a strong management team as it enters the US generic space.

Name	Designation	Hired in	Previous Company
Mr. Sreekanth Muttineni	COO	16-Sep	Aurobindo Pharma
Mr. Ganesh K	CFO	17-May	Dr. Reddy
Mr M Gopi Reddy	Sr. VP - Quality	16-Sep	Cipla
Mr. Jaishokan Velusami	Hear - R&D (Granules Pharma Inc.)	16-Apr	Actavis & Par Pharma Inc.

Management team profile

Mr C. Krishna Prasad – Chairman and Managing Director

Mr Prasad is the founder of Granules and has three decades of experience in the pharmaceutical industry. In 1984, he set up a Paracetamol manufacturing facility, focused on capital and process efficiency. Pharmaceutical Formulations Intermediates (PFIs) as a cost-efficient product for global formulations manufacturers is a concept pioneered and popularized by him.

Dr. Prasada Raju – Executive Director

Dr Raju has over two decades of techno commercial experience in the global pharmaceutical space. His previous experience at Dr Reddy's encompasses new product development, fostering strategic partnerships, driving synergies between Industry and Academia, expanding into newer geographies, IP-driven early product portfolio development and program management.

Mr Sreekanth Muttineni – Chief Operating Officer

Mr Muttineni joined Granules India in September 2016. During his nine-year tenure at Lupin Ltd, he was responsible for manufacturing operations. Prior to that, Mr Muttineni worked at Aurobindo Pharma as general manager – operations, and led the establishment of generic pharmaceutical facilities and commercialization.

Mr. Ganesh K – Chief Financial Offer

Mr. Ganesh joined Granules India in May 2017. Before joining Granules, he was associated with Dr Reddy's for a span of 12 years as senior vice president – corporate finance. Mr Ganesh is a chartered accountant, having professional experience of more than 27 years. He specializes in leading large-scale M&A and treasury operations, with skills in executing business/financial management strategies and strengthening fiscal efficiency.

Mr M Gopi Reddy – Sr. Vice President (Quality)

Mr Reddy joined Granules India in September 2016. He started his career 1995 as assistant manager production at GSK Pharma, where he worked for six years. He has 21 years of experience in corporate quality assurance, working with some of the biggest pharma companies in India. In his previous stint in Cipla as head quality compliance, he was responsible for developing systems and skills to ensure compliance at all the company's manufacturing sites globally.

Mr Jaishokan Velusami – Head R&D (Granules Pharmaceuticals Inc.)

Mr Velusami has over 15 years of extensive multi-disciplinary expertise in drug development and portfolio management across a broad range of therapeutic areas, drug delivery systems and novel platform technologies. His extensive experience includes technology transfer, commercializing R&D assets, strategic planning and optimizing operation strategy across cross-functional teams. Prior to Granules, he led R&D programs at Actavis and Par Pharmaceutical Inc., and has also laid the foundation for successful start-ups (Novel and Kali Laboratories) in drug development and operational strategy.

Mr. Stefan Lohle – Chief Marketing Officer

Mr Lohle has over two decades of experience in the pharmaceutical industry. He has been associated with Granules since 2001, and previously was head of Latin American operations, where he primarily focused on the PFI business. Mr Lohle has also served at Kimberly Clark Corporation for new project development.

Story in charts

Exhibit 12: Revenues to exhibit 27% CAGR over FY17-20E




Exhibit 13: Revenues from US biz to drive growth




Exhibit 14: EBITDA margins to expand to 23% by FY20E




Exhibit 15: PAT to exhibit 35% CAGR over FY17-20E




Exhibit 16: Geo-graph- wise revenue break-up




Exhibit 17: Product mix changing (%)




Exhibit 18: Capex needs to continue with growth





Exhibit 19: Return ratios to improve post FY18



Source: Company, MOSL

Source: Company, MOSL

Valuation and view

Over last six years, GRAN reported a 39% earnings CAGR, led by improved profitability, higher operating leverage and a superior business mix. The company expanded its finished dosages business at a CAGR of 36% over FY11-16, leading to higher profitability and improved utilization of the existing capacity of 18b tablets. Profitability of the PFI business has also improved substantially, with the implementation of 6MT order capacity. As a result, GRAN has expanded its EBITDA margin from 11.8% in FY11 to ~21% in FY17.

We expect ~35% PAT CAGR to continue till FY20E, supported by ~27% revenue CAGR and ~250bp margin expansion. Our target price of INR200 discounts FY19E EPS at 18x, which (a) is at a 5-10% premium to peers and (b) implies a PEG of 0.5x (FY17-20E EPS CAGR of ~30%).

GRAN is trading at ~13x FY19E EPS. We argue for a P/E re-rating for GRAN, given (a) strong PAT growth outlook and (b) expansion in its high-margin CRAMs and US generic business.

Exhibit 20: Peer comparison

	CMP	Mkt. CAP (USD m)	P/E		EV/EBITDA		RoE (%)	
			FY18E	FY19E	FY18E	FY19E	FY18E	FY19E
Granules India	149	535	13.1	9.4	8.9	6.6	16.3	17.2
Marksans Pharma	50	314	25.4	17.7	14.2	10.6	16.0	19.8
Shilpa Medicare	718	889	32.9	22.8	22.2	16.5	19.2	23.0
Dishman Pharma	299	743	18.6	14.8	11.1	9.6	14.1	15.9
IPCA	530	1040	21.0	15.8	11.8	9.5	12.4	14.4
Suven	184	363	20.2	17.6	13.2	11.4	16.2	16.5
Neuland	1450	199	24.7	16.8	11.9	9.0	23.4	27.1


Key catalysts to drive stock performance over medium term

- Finished dosage product approvals from regulated markets
- Commercialization of new capacity
- Higher-than-expected realizations from Omnicem JV

Risks to our investment thesis


- Pricing pressure on existing products
- Regulatory risks related to already approved manufacturing facilities

Exhibit 21: P/E band – significant re-rating over past 30 months



Source: MOSL, Company

Exhibit 22: P/E relative to Sensex



Source: MOSL, Company

Financials and Valuations

Income Statement							(INR Million)	
Y/E Mar	2012	2013	2014	2015	2016	2017	2018E	2019E
Net Sales	6,540	7,644	10,959	12,929	14,295	14,353	17,051	23,390
Change (%)	37.6	16.9	43.4	18.0	10.6	0.4	18.8	37.2
EBITDA	793	851	1,583	2,086	2,767	2,988	3,683	5,239
EBITDA Margin (%)	12.1	11.1	14.4	16.1	19.4	20.8	21.6	22.4
Depreciation	207	231	298	527	643	715	1,018	1,481
EBIT	586	620	1,285	1,560	2,124	2,273	2,664	3,759
Interest	170	177	204	323	399	323	326	541
Other Income	14	21	43	43	77	99	140	140
Extraordinary items	0	0	0	0	0	0	0	0
PBT	430	464	1,124	1,280	1,802	2,050	2,479	3,358
Tax	130	138	371	371	617	643	793	1,074
Tax Rate (%)	30.3	29.7	33.0	29.0	34.2	31.4	32.0	32.0
Min. Int. & Assoc. Share	0	0	0	0	0	-247	-375	-600
Reported PAT	300	326	753	909	1,185	1,654	2,060	2,883
Adjusted PAT	300	326	753	909	1,185	1,654	2,060	2,883
Change (%)	43.3	8.8	130.8	20.8	30.3	39.6	24.6	39.9

Balance Sheet							(INR Million)	
Y/E Mar	2012	2013	2014	2015	2016	2017	2018E	2019E
Share Capital	201	201	203	204	217	228	253	253
Reserves	2,250	2,547	3,357	4,107	6,444	9,683	15,035	17,241
Net Worth	2,451	2,749	3,560	4,312	6,660	9,911	15,288	17,494
Debt	2,036	2,705	4,417	4,872	4,767	6,517	6,517	7,017
Deferred Tax	230	245	303	493	580	580	580	580
Total Capital Employed	4,717	5,698	8,280	9,676	12,008	17,008	22,386	25,092
Gross Fixed Assets	3,545	3,874	6,539	8,438	9,622	12,992	18,492	20,992
Less: Acc Depreciation	1,041	1,240	1,714	2,272	2,941	3,656	4,674	6,155
Net Fixed Assets	2,504	2,635	4,825	6,166	6,681	9,336	13,818	14,837
Capital WIP	293	1,088	1,246	620	766	1,005	1,023	1,403
Investments	2	97	2	2	2	2	2	2
Current Assets	2,914	3,007	3,848	5,184	7,080	9,120	10,398	12,539
Inventory	1,099	1,365	1,742	2,245	3,071	2,802	3,296	4,475
Debtors	950	710	1,109	1,326	1,526	3,932	4,671	6,088
Cash & Bank	320	417	418	653	1,419	1,317	1,160	233
Loans & Adv, Others	545	515	580	959	1,065	1,069	1,270	1,742
Curr Liabs & Provns	996	1,128	1,640	2,295	2,521	2,455	2,854	3,689
Curr. Liabilities	934	1,061	1,517	2,120	2,399	2,167	2,373	2,984
Provisions	62	68	123	175	122	288	481	706
Net Current Assets	1,918	1,879	2,208	2,888	4,559	6,665	7,543	8,850
Total Assets	4,717	5,698	8,280	9,676	12,008	17,008	22,386	25,092

Financials and Valuations

Ratios

Y/E Mar	2012	2013	2014	2015	2016	2017	2018E	2019E
Basic (INR)								
EPS	1.5	1.6	3.7	4.5	5.5	7.3	8.1	11.4
Cash EPS	2.5	2.8	5.2	7.0	8.4	10.4	12.2	17.2
Book Value	12.2	13.7	17.6	21.1	30.7	43.5	60.4	69.1
DPS	0.2	0.2	0.4	0.5	0.6	1.0	1.5	2.2
Payout (incl. Div. Tax.)	15.6	14.4	11.0	13.6	13.9	16.2	22.2	23.5
Valuation(x)								
P/E				33.4	27.2	20.5	18.3	13.1
Price / Book Value				7.0	4.8	3.4	2.5	2.2
EV/Sales				2.4	2.1	2.2	1.9	1.4
EV/EBITDA				15.0	11.0	10.8	8.8	6.5
Dividend Yield (%)				0.3	0.4	0.7	1.0	1.5
Profitability Ratios (%)								
RoE	12.9	12.5	23.9	23.1	21.6	20.0	16.4	17.6
RoCE	15.2	12.9	19.8	18.7	21.4	17.0	14.7	16.8
RoIC	10.8	10.6	15.9	14.6	15.2	12.7	10.3	11.7
Turnover Ratios (%)								
Asset Turnover (x)	1.4	1.3	1.3	1.3	1.2	0.8	0.8	0.9
Debtors (No. of Days)	52	33	36	36	38	98	98	93
Inventory (No. of Days)	61	65	58	63	78	71	71	70
Creditors (No. of Days)	67	72	77	92	86	84	75	67
Leverage Ratios (%)								
Net Debt/Equity (x)	0.7	0.8	1.1	1.0	0.5	0.5	0.4	0.4

Cash Flow Statement

(INR Million)

Y/E Mar	2012	2013	2014	2015	2016	2017	2018E	2019E
Adjusted EBITDA	793	851	1,583	2,086	2,767	2,988	3,683	5,239
Non cash opr. exp (inc)	7	8	29	29	25	0	0	0
(Inc)/Dec in Wkg. Cap.	-436	146	-310	-363	-915	-2,208	-872	-2,030
Tax Paid	-115	-112	-238	-317	-490	-652	-793	-1,074
Other operating activities	7	19	16	18	51	0	-163	-203
CF from Op. Activity	256	912	1,080	1,453	1,438	128	1,855	1,932
(Inc)/Dec in FA & CWIP	-550	-1,163	-2,649	-1,473	-1,335	-3,609	-5,518	-2,880
Free cash flows	-294	-251	-1,570	-20	103	-3,481	-3,663	-948
(Pur)/Sale of Invt	2	-95	95	0	0	0	0	0
Others	3	-20	8	17	53	99	140	140
CF from Inv. Activity	-545	-1,278	-2,546	-1,456	-1,281	-3,510	-5,378	-2,740
Inc/(Dec) in Net Worth	0	6	11	11	1,059	1,873	3,775	0
Inc / (Dec) in Debt	691	682	1,709	628	191	1,750	0	500
Interest Paid	-168	-178	-205	-319	-406	-323	-326	-541
Divd Paid (incl Tax) & Others	-35	-47	-47	-83	-234	-21	-83	-77
CF from Fin. Activity	489	463	1,467	238	609	3,280	3,367	-119
Inc/(Dec) in Cash	200	97	0	236	766	-102	-157	-927
Add: Opening Balance	120	320	417	417	653	1,419	1,317	1,160
Closing Balance	320	417	417	653	1,419	1,317	1,160	233

NOTES

Disclosures

This document has been prepared by Motilal Oswal Securities Limited (hereinafter referred to as Most) to provide information about the company (ies) and/or sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies). This report is for personal information of the selected recipient/s and does not constitute to be any investment, legal or taxation advice to you. This research report does not constitute an offer, invitation or inducement to invest in securities or other investments and Motilal Oswal Securities Limited (hereinafter referred to as MOST) is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your general information and should not be reproduced or redistributed to any other person in any form. This report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, investors should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur.

MOST and its affiliates are a full-service, integrated investment banking, investment management, brokerage and financing group. We and our affiliates have investment banking and other business relationships with a some companies covered by our Research Department. Our research professionals may provide input into our investment banking and other business selection processes. Investors should assume that MOST and/or its affiliates are seeking or will seek investment banking or other business from the company or companies that are the subject of this material and that the research professionals who were involved in preparing this material may educate investors on investments in such business. The research professionals responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting information. Our research professionals are paid on twin parameters of performance & profitability of MOST.

MOST generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, MOST generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing among other things, may give rise to real or potential conflicts of interest. MOST and its affiliated company(ies), their directors and employees and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the affiliates of MOST even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report

Reports based on technical and derivative analysis center on studying charts company's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamental analysis. In addition MOST has different business segments / Divisions with independent research separated by Chinese walls catering to different set of customers having various objectives, risk profiles, investment horizon, etc, and therefore may at times have different contrary views on stocks sectors and markets.

Unauthorized disclosure, use, dissemination or copying (either whole or partial) of this information, is prohibited. The person accessing this information specifically agrees to exempt MOST or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOST or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOST or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays. The information contained herein is based on publicly available data or other sources believed to be reliable. Any statements contained in this report attributed to a third party represent MOST's interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. This Report is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. While we would endeavor to update the information herein on reasonable basis, MOST and/or its affiliates are under no obligation to update the information. Also there may be regulatory, compliance, or other reasons that may prevent MOST and/or its affiliates from doing so. MOST or any of its affiliates or employees shall not be in any way responsible and liable for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. MOST or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

This report is intended for distribution to institutional investors. Recipients who are not institutional investors should seek advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents.

Most and its associates may have managed or co-managed public offering of securities, may have received compensation for investment banking or merchant banking or brokerage services, may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Most and its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.

Subject Company may have been a client of Most or its associates during twelve months preceding the date of distribution of the research report

MOST and/or its affiliates and/or employees may have interests/positions, financial or otherwise of over 1% at the end of the month immediately preceding the date of publication of the research in the securities mentioned in this report. To enhance transparency, MOST has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report.

Motilal Oswal Securities Limited is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014. SEBI Reg. No. INH00000412

Pending Regulatory inspections against Motilal Oswal Securities Limited:

SEBI pursuant to a complaint from client Shri C.R. Mohanraj alleging unauthorized trading, issued a letter dated 29th April 2014 to MOSL notifying appointment of an Adjudicating Officer as per SEBI regulations to hold inquiry and adjudicate violation of SEBI Regulations; MOSL replied to the Show Cause Notice whereby SEBI granted us an opportunity of Inspection of Documents. Since all the documents requested by us were not covered we have requested to SEBI vide our letter dated June 23, 2015 to provide pending list of documents for inspection.

List of associate companies of Motilal Oswal Securities Limited - [Click here to access detailed report](#)

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The research analysts, strategists, or research associates principally responsible for preparation of MOST research receive compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues

Disclosure of Interest Statement

- Analyst ownership of the stock
- Served as an officer, director or employee -

GRANULES INDIA

No
No

A graph of daily closing prices of securities is available at www.nseindia.com and <http://economictimes.indiatimes.com/markets/stocks/stock-quotes>

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOST & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong: This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg No. INH00000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Securities Limited (MOSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act") and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOSL, including the products and services described herein are not available to or intended for U.S. persons.

This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

Motilal Oswal Capital Markets Singapore Pte Limited is acting as an exempt financial advisor under section 23(1)(f) of the Financial Advisers Act (FAA) read with regulation 17(1)(d) of the Financial Advisers Regulations and is a subsidiary of Motilal Oswal Securities Limited in India. This research is distributed in Singapore by Motilal Oswal Capital Markets Singapore Pte Limited and it is only directed in Singapore to accredited investors, as defined in the Financial Advisers Regulations and the Securities and Futures Act (Chapter 289), as amended from time to time.

In respect of any matter arising from or in connection with the research you could contact the following representatives of Motilal Oswal Capital Markets Singapore Pte Limited:

Varun Kumar
Varun.kumar@motilaloswal.com
Contact : (+65) 68189232
Office Address: 21 (Suite 31), 16 Collyer Quay, Singapore 04931



Motilal Oswal Securities Ltd

Motilal Oswal Tower, Level 9, Sayani Road, Prabhadevi, Mumbai 400 025

Phone: +91 22 3982 5500 E-mail: reports@motilaloswal.com